Sylentis is a biotechnology company focused on the research, development, and commercialization of innovative RNA therapeutics for the treatment of ophthalmological diseases.  Sylentis's self-described mission is to improve patients' lives through the development of new treatments.

Sylentis

SERI Lugano is involved in research and innovation in vision, focusing on advanced ophthalmic treatments and therapies for various eye conditions.

SERI Lugano

Dry Eye Centre specializes in the analysis and treatment of mild to severe dry eyes, self-described as the first clinic in the UK dedicated solely to this.

Dry Eye Centre

Sylentis is a biopharmaceutical company focused on developing RNAi-based treatments for ophthalmological diseases, particularly targeting conditions like dry eye syndrome, macular degeneration, and ocular allergies.

siRNA Technology

SYLENTIS | 6,459 followers on LinkedIn. Sylentis is an European biotechnological company founded in 2006. Sylentis focuses on researching new therapeutic approaches based on gene silencing. Our company is specialised in developing ophtalmologic   therapies via interference RNA, a powerful tool for rational drug design.

Andreas Segerros

Triple Master in Risk Prevention, Quality and Environment Management. European Quality Formation

Marina Alonso Sanchez

Responsable de producción en Sylentis/ Docente MASTER Industria Farmacéutica

Elsa Rodríguez Puerta

Production Technician in Sylentis

Bruno Barbón González

SYLENTIS

This week, SYLENTIS will be participating in the 20th Annual Meeting Oligonucleotide Therapeutics Society. Please visit our booth!! Oligonucleotide Therapeutics Society #oligonucleotidos #OTS2024 #RNAi #oligotherapeutic

👉 Ana Isabel Jiménez , General Director, and Eva García Fernández , Business Development Manager, are representing SYLENTIS and the #OLIGOFASTX consortium at the Oligonucleotide Therapeutics Society being held these days in Montreal, Canada. Sharing experiences in a meeting of the leading experts in #oligonucleotide development. 🧬 📌 https://cstu.io/d1610c #fundedbyCDTI

OLIGOFASTX

The 2024 Nobel Prize in Physiology or Medicine has been awarded today to Victor Ambros and Gary Ruvkun for their discovery of microRNA and its role in post-transcriptional gene regulation. They identified microRNA, a novel class of small RNA molecules that play a crucial role in gene expression control. Their seminal discovery was reported in two papers published back-to-back in Cell in 1993 (Lee, Feinbaum and Ambros, 1993; Wightman, Ha and Ruvkun, 1993). It is now known that the human genome encodes over a thousand microRNAs, adding a whole new layer to the complexity of gene regulation. Their remarkable discovery has opened an unexpected and revolutionary dimension to our understanding of biology. Congratulations to the honorees! And of course, a big thank you for their invaluable contributions to RNA research and gene regulation. 👏 For the second year in a row, RNA takes center stage at the Nobel Prize in Medicine. At Sylentis, we proudly celebrate the growing awareness of this vital molecule for life, around which our work revolves. #oligonucleotides #RNA #microRNA #siRNA #Sylentis #NobelPrize 👉 https://lnkd.in/eFU7DuZf

🔸Innovations in Oligonucleotide Therapeutics Manufacturing to Responsibly Meet Future Demand🔸 Join us at the Oligonucleotide Therapeutics Society Congress 2024 for our poster ( #P076 ) presentation on Monday, October 7, from 5:00 pm to 8:00 pm! 📍 We look forward to engaging with fellow professionals and discussing how we can collectively drive innovation in oligonucleotide manufacturing. Don’t miss it! #Oligonucleotides #Innovation #Sustainability #Manufacturing #CDMO #SylentisCDMO #OTS2024

OTS Congress 2024 is close!! The 20th Annual Meeting of the Oligonucleotide Therapeutics Society will be held from October 6 to 9 in Montreal, Canada. 📆 Sylentis will be there at booth 4-15. 📧🗣 Contacts: Ana Isabel Jiménez and Eva García Fernández 🎯 Know Sylentis CDMO: Oligonucleotides manufacturing – Therapeutic Oligos – GMP Solutions – RNA&DNA – Extensive expertise – Customized Services See you there!

It is estimated that 1 in 3,000 – 4,000 of the world’s population suffers from retinitis pigmentosa, and it is the leading cause of total blindness. At Sylentis and within the Oligofastx project, we work to develop an oligo-based new therapy for this Ophthalmological disease #WorlRetinitisPigmentosaDay2024 #Oligonucleotides #NewTherapies

We had a fantastic time at FARMAFORUM 2024 !! It was a pleasure connecting with so many professionals and companies in the pharma sector, and we look forward to building on the exciting conversations and opportunities that were discussed. We would like to thank the organizers for giving my colleague Verónica Ruz the opportunity to participate in the clinical research forum. Looking forward to next year’s edition! SYLENTIS

Ana Isabel Jiménez

📆 Today at FARMAFORUM 2024 ... We were thrilled to participate in the roundtable discussion “Risk-Based Quality Management in Clinical Trials: Innovations and Practical Improvements” 🙌 Our colleague Veronica Ruz , along with the other panelists, engaged in a fascinating discussion, sharing valuable insights and exploring key issues on this important topic. Thank you to all the participants, organizers, and attendees! #ClinicalResearchForum #ClinicalResearch #Sylentis #Quality

SYLENTIS is part of the consortium leading SECRETed Project H2020 . Don't miss the chance to learn more about this exciting European project at FARMAFORUM 2024 💧 #H2020 #Sustainability

Asiste a la Mesa Redonda 👉Implementación y Desafíos de la Gestión de Calidad Basada en Riesgos ( #RBQM ) en #EnsayosClínicos : Innovaciones y Mejoras Prácticas El evento forma parte de la agenda de la Feria FARMAFORUM 2024 que se celebrará el 25 y 26 de septiembre en IFEMA, Madrid La Mesa Redonda será moderada por Marta Valverde Collazo , responsable del Área de Investigación Clínica, KONEXIO BIOTECH cuenta con la participación de: 👩💼 Ana Maria Tello Miller , Clinical Monitoring Unit Head, Sermes CRO 👩💼 Dr. Leire Zúñiga, PharmD, PhD , CEO Pharmity ; Chief Quality Officer (CQO), Qlarix Healthcare Solutions 👩💼 Veronica Ruz , responsable de Asuntos Regulatorios y QA, Director Técnico, SYLENTIS 👩💼Yolanda Lara, Associate Director, Project Management, Global CRO; Vocal de Investigación Clínica, AEFI - Asociación Española de Farmacéuticos de la Industria 👨💼 Antonio Llamas , Associate Director, Clinical Operations Late Phase, Gilead Sciences 👨💼 Carlos Palacios Associate Director, Oncology, Clinical Operations, Gilead Sciences Será el 26.09.2024 a partir de las 12:30h en la Sala: Farmaforum / Clinical Research Forum en el Pabellón 9 de IFEMA. Registro online👉 https://lnkd.in/eDUss4d9

Metric
Company Name	Sylentis	SERI Lugano	Dry Eye Centre
Symbol
MSH ID	COM:SYLENTIS	CH:SERI-LUGANO	UK:CO:DRYEYECENTRE
Market	PRIVATE	PRIVATE	PRIVATE
Sector	Healthcare & Health Services	Healthcare & Health Services	Healthcare & Health Services
Industry	Biotechnology	Medical & Healthcare	Medical Services
Country	ES	CH	GB
Stage
Employee Count
Website	sylentis.com	seri-lugano.ch	dryeyecentre.co.uk
LinkedIn	sylentis	seri-lugano
Founders

Metric
Market Cap
Enterprise Value
Monthly Web Traffic	8.09K
Web Traffic Growth	11.97
Valuation
Raised Capital

Metric
Revenue
Revenue (LTM)
Revenue (NTM)
Gross Profit
EBITDA
Operating Income
Net Income
EPS
Diluted EPS
Revenue 2022
Revenue 2023
Revenue 2024
Revenue 2025
Revenue 2026

Metric
Revenue Growth (LTM)
Revenue Growth (NTM)
Gross Profit Growth (LTM)
EBITDA Growth (LTM)
Net Income Growth (LTM)
14-Day Growth Score
28-Day Growth Score
90-Day Growth Score
365-Day Growth Score

Metric
Gross Profit Margin
Operating Profit Margin
EBITDA Margin
Net Profit Margin
Return on Equity
Return on Assets
Return on Capital Employed

SYLE

COM:SYLENTIS

Sylentis

Company Overview

Market Metrics

Financial Performance

Growth Metrics

Profitability Ratios

Valuation Multiples

Operational Metrics

Cash Flow Metrics

Balance Sheet Metrics

Efficiency Metrics

Metric
P/E Ratio
P/B Ratio
Revenue Multiple (LTM)
Revenue Multiple (NTM)
EBITDA Multiple (LTM)
EBITDA Multiple (NTM)
Price to Sales Ratio
EV Multiple

Metric
Days Sales Outstanding
Days Payables Outstanding
Days Inventory Outstanding
Operating Cycle
Cash Conversion Cycle
Asset Turnover

Metric
Operating Cash Flow
Free Cash Flow
Cash Flow to Debt
Operating Cash Flow/Sales
Free Cash Flow Yield

Metric
Cash & Equivalents
Accounts Receivable
Inventory
Goodwill
Debt to Capitalization
Debt to Assets
Current Ratio
Quick Ratio

Metric
Rule of 40 (LTM)
Rule of 40 (NTM)
Stock Comp to Revenue
R&D to Revenue
SG&A to Revenue